|
Year |
Author |
Title |
Journal/Meeting |
Type |
|
2006 |
Brown A, Aristides M, Fitzgerald P, Liepa A, Boyer M, Clarke S |
Patient preference and willingness-to-pay for pemetrexed versus docetaxel in the second-line |
ISPOR 2nd Asia-Pacific Congress, |
Poster |
|
2006 |
Davey P, Cordony a, Rajan N, Arora B, Pavlakis |
Cost-effectiveness of pemetrexedplus cisplatin versus cisplatin alone in the treatment of malignant pleuralmesothelioma. |
ISPOR 2nd Asia-Pacific Congress, |
poster |
|
2005 |
Chetty M, Cordony A, Davey P, Karampela K, Symanowski J, Le Reun C, Watt M |
Economic impact of adopting pemetrexed plus cisplatin for malignant pleural mesothelioma into Scottish clinical practice. |
ISPOR 8th European Congress, Florence, Italy |
Poster |
|
2005 |
Davey P, Cordony A, Rajan N, Arora B, Pavlakis N |
Value-for-money of pemetrexed plus cisplatin versus cisplatin alone in the treatment of malignant pleural mesothelioma. |
ISPOR 10th International Meeting, Washington DC, USA |
Poster |
|
2005 |
Demarteau N, Moeremans K, Annemans L |
Critical appraisal of scientific posters comparing anemia treatments in cancer patients: applying ISPOR task force guidelines on methodological quality of retrospective studies. |
ISPOR 8th European Congress, Florence, Italy |
Poster |
|
2005 |
Gabriel A, Haenel M, Wehmeyer J, Griesinger F |
Advantages in cost effectiveness of Zevalin® radioimmunotherapy vs. rituximab immunotherapy in patients with relapsed or refractory follicular non-Hodgkin´s lymphoma. |
Onkologie; 28 (Suppl 3):730 |
Abstract |
|
2005 |
Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R et al. |
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum-containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. |
Lung Cancer; 47:69-80 |
Review |
|
2005 |
Moeremans K, Annemans L |
Health economic evaluation based on the 5-year completed treatment analysis of the atac trial comparing anastrozole versus tamoxifen in adjuvant treatment of postmenopausal hormone receptor positive early breast cancer. |
ISPOR 8th European Congress, Florence, Italy |
Poster |
|
2005 |
Moeremans K, Annemans L |
Health economic evaluation based on the 5-year completed treatment analysis of the ATAC trial comparing anastrozole versus tamoxifen in adjuvant treatment of postmenopausal hormone receptor positive early breast cancer. |
ISPOR 8th European Congress, Florence, Italy |
Poster |
|
2005 |
Moeremans* K, Annemans L |
Cost drivers in multiple myeloma treatment – a 2 year analysis from a multicountry retroprojected chart review. |
ISPOR 8th European Congress, Florence, Italy |
Poster |
|
2005 |
Moeremans K, Caekelbergh K, Spaepen E, Annemans L |
Cost drivers in multiple myeloma treatment – A two year analysis from a multicountry retroprojected chart review ISPOR. |
ISPOR 8th European Congress, Florence, Italy |
Poster |
|
2005 |
Moeremans K, Caekelbergh K, Spaepen E, Annemans L |
Economic aspects and drivers of febrile neutropenia in cancer – a multicentre retrospective analysis in Belgium. |
ISPOR 8th European Congress, Florence, Italy |
Poster |
|
2005 |
Novello S, Kielhorn A, Stynes G, Selvaggi G, De Marinis F, Maestri A et al. |
Italian Lung Cancer Project Investigators. 2005. Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy. |
Lung Cancer; 48:379-87 |
Manuscript |
|
2005 |
Stynes G, Gatzemeier U, Thatcher N, Bhalla S, Aristides M, Leschinger M et al. |
Do the published toxicity data from clinical trials in oncology give the full picture? An example using pemetrexed and docetaxel. |
Proceedings of the American Society of Clinical Oncology Annual Meeting.Journal of Clinical Oncology; 23 (Suppl 16S): 8188 |
Abstract |
|
2005 |
Tilden D, Hill G, Watt M, Bhalla S |
A pilot study assessing the quality of life impact of adverse events experienced by advanced non-small-cell lung cancer patients receiving second-line chemotherapy. |
ISPOR 8th European Congress, Florence, Italy |
Poster |
|
2005 |
Tilden D, Thurley D, White J, Aristides, M |
The cost-effectiveness of cetuximab in combination with irinotecan for the treatment of patients with EGFR-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy in Scotland. |
ISPOR 8th European Congress, Florence, Italy |
Poster |
|
2005 |
Blamey S, Barraclough B, Delbridge L, Mernagh P, Standfield L, Weston A |
Using recombinant human thyroid-stimulating hormone for the diagnosis of recurrent thyroid cancer. |
ANZ Journal of Surgery; 75: 10-20 |
Manuscript |
|
2004 |
Helmberger T, Annemans L, Warie H, Muller U |
Health economic evaluation of liver MRI in colorectal cancer patients. |
Eur Radiol; 14 (Suppl 1):C13 |
Manuscript |
|
2004 |
Moeremans K, Caekelbergh K, Annemans L |
Cost-effectiveness analysis of bicalutamide (Casodex) for adjuvant treatment of early prostate cancer. |
Value Health; 7:472-81 |
Manuscript |
|
2004 |
Robinson P, von der Maase H, Bhalla S, Kielhorn A, Aristides M, Brown A et al. |
Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer. |
Expert Review of Pharmacoeconomics and Outcomes Research; 4:27-38 |
Manuscript |
|
2004 |
Schiller J, Tilden D, Aristides M, Lees M, Kielhorn A, Maniadakis N et al. |
Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. |
Lung Cancer; 43:101–112 |
Manuscript |
